Xenon Pharmaceuticals Inc. — Director's Dealing 2021

Mar 15, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Xenon Pharmaceuticals Inc. (XENE)
CIK: 0001582313
Period of Report: 2021-03-12

Reporting Person: ROBIN SHERRINGTON (EVP, Strategy & Innovation)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-12	Stock Option (Right to Buy)	$20.55	A	65000	Acquired	2031-03-11	Common Shares (65000)	Direct

Footnotes

F1: Vesting 25% on January 1, 2022 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.